Hereditary Breast/Ovarian Cancer (brca1, brca2)
9
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Evaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction
Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Genetics and Heart Health After Cancer Therapy
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer